[Skip to Navigation]
February 1984

Hearing Loss and Erythromycin Pharmacokinetics in Patients Receiving Hemodialysis-Reply

Author Affiliations


Arch Intern Med. 1984;144(2):420. doi:10.1001/archinte.1984.00350140253047

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In Reply.  —The information provided by Drs Méry and Kanfer is a valuable addition to the literature on erythromycin pharmacokinetics in disease states. Steady-state plasma concentration and interpatient variability data are needed before definitive recommendations can be made for erythromycin dosing in the presence of renal insufficiency. A risk-benefit analysis of the severity of the infection v the risk of ototoxicity should be made for each patient. Patient body weight must also be considered in the choice of dose. Based on our knowledge, it seems reasonable to restrict the erythromycin dose to 1 g/day for infections of mild to moderate severity in adults with renal insufficiency. However, larger doses may be needed for the treatment of severe infections, eg, those due to Legionella sp.

First Page Preview View Large
First page PDF preview
First page PDF preview
Add or change institution